AML, acute myeloid leukaemia; Ph+ CML, Philadelphia-positive (Ph+) chronic myeloid leukaemia; NA, not available; VAF, variant allele frequency; CR, complete remission;
MRD, minimal residual disease; Allo-HSCT, allogeneic haematopoietic stem cell transplantation; HD, high dose; ARA-C, cytarabine; ASP, asparaginase; AMSA, amsacrine; 6-MP, mercaptopurine; 3+7: Cytarabine+Daunorubicin; ICE: Idarubicine, Cytarabine and etoposide; PBSC, peripheral blood stem cells; Ven, venetoclax; IC: Idarubicine, Cytarabine; VUD, volunteer unrelated donor; GO, gentuzumab ozogamicin.
*Next generation sequencing analysis of PB DNA using the Oncomine Myeloid Research Assay and the Ion Torrent S5 technology (ThermoFisher).